The UK's health regulator, the MHRA, is investigating the association of GLP-1 receptor agonist drugs, such as Ozempic and Mounjaro, to serious health issues including nearly 300 cases of pancreatitis and at least 10 related deaths. The investigation follows a government initiative encouraging residents to report any adverse effects through the 'Yellow Card' scheme. Despite assurances from healthcare providers about the safety of these medications, new data raises concerns just as the NHS begins to allow prescriptions for Mounjaro under specific eligibility criteria, emphasizing the importance of monitoring these drugs' side effects.
The UK Medicines and Healthcare products Regulatory Agency is investigating GLP-1 weight loss drugs after linking them to hundreds of severe illnesses and a handful of deaths.
The country's NHS just began allowing prescriptions for Mounjaro while urging residents to report adverse drug events related to GLP-1s to the MHRA's Yellow Card campaign.
In total, there were nearly 300 reported cases of pancreatitis and at least 10 pancreatitis-related deaths connected to these GLP-1 weight loss medications.
Doctors stress that while GLP-1s are generally considered safe, the new information highlights the need for further scrutiny and resident reporting of adverse effects.
Collection
[
|
...
]